We find that mutations in the TP53, FLT4, EYA1, NCOR2, CSMD3, and PCDH15 genes are associated with prostate cancer metastasis and mutations in EYA1 and CSMD3 are associated with poor outcome. This evidence concerns the gene PCDH15 and prostate carcinoma.